Literature DB >> 8384963

Pleural effusion in lung cancer.

S A Sahn1.   

Abstract

Pleural effusions are common in the setting of lung cancer. A pleural effusion associated with lung cancer is an ominous finding, but a small percentage of patients are candidates for curative surgery. The clinician must establish whether the effusion is malignant, excluding the possibility of curative surgery; paramalignant, which may or may not exclude surgery; or whether it is unassociated with cancer. When a malignant pleural effusion is diagnosed, the clinician must decide on the most appropriate form of palliation for the symptomatic patient. In the symptomatic patient with a reasonable life expectancy and pleural fluid pH of more than 7.3, chemical pleurodesis appears to be the most effective and least morbid therapy.

Entities:  

Mesh:

Year:  1993        PMID: 8384963

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  10 in total

1.  Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis.

Authors:  G Paone; G De Angelis; S Greco; F Fiorucci; A Bisetti; F Ameglio
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

3.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 4.  Staging for M disease.

Authors:  T L Winton
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

5.  Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions.

Authors:  R K Batra; J C Olsen; D K Hoganson; B Caterson; R C Boucher
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

6.  Detection of malignant cells in pleural fluid or ascites by CD44v8-10/CD44v10 competitive RT-PCR.

Authors:  M J Ahn; Y H Noh; H J Yoon; S C Yang; J W Sohn; J H Choi; Y Y Lee; I Y Choi; I S Kim; Y S Lee; C K Park
Journal:  Korean J Intern Med       Date:  2001-03       Impact factor: 2.884

7.  Primary thoracoscopic evaluation of pleural effusion with local anesthesia: an alternative approach.

Authors:  Sadir J Alrawi; Ramanathan Raju; Anthony J Acinapura; Joseph N Cunningham; Jeffrey S Cane
Journal:  JSLS       Date:  2002 Apr-Jun       Impact factor: 2.172

8.  The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer.

Authors:  Saroj K Basak; Mysore S Veena; Scott Oh; Ge Huang; Eri Srivatsan; Min Huang; Sherven Sharma; Raj K Batra
Journal:  PLoS One       Date:  2009-06-12       Impact factor: 3.240

9.  Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.

Authors:  Nikolaos Barbetakis; Theodoros Antoniadis; Christodoulos Tsilikas
Journal:  World J Surg Oncol       Date:  2004-05-20       Impact factor: 2.754

10.  Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.

Authors:  Nikolaos Barbetakis; Michalis Vassiliadis; Konstantinos Kaplanis; Rosalia Valeri; Christodoulos Tsilikas
Journal:  BMC Palliat Care       Date:  2004-09-09       Impact factor: 3.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.